Drug intelligence / Profile preview

GLS-3000

Development stage: Preclinical
Lead developer: GeneOne Life Science
Modality: Small Molecules

Overview

GLS-3000 is a preclinical-stage small molecule therapeutic candidate developed by GeneOne Life Science for the treatment of COVID-19. It functions as a SARS-CoV-2 spike (S) protein inhibitor, designed to block the interaction between the viral spike protein and host cell receptors, thereby preventing viral entry and infection. Unlike many spike-targeting agents that are monoclonal antibodies, GLS-3000 represents a small molecule approach to inhibiting the SARS-CoV-2 virus.

Other names: GLS-3000GLS3000GLS 3000

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on GLS-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLS-3000.

Explore the full profile